Talzenna (talazoparib) — CareFirst (Caremark)
Breast cancer
Initial criteria
- For breast cancer: member has breast cancer with no response to preoperative systemic therapy OR locally advanced, recurrent, or metastatic breast cancer; AND member has deleterious or suspected deleterious germline BRCA mutation.
- For metastatic castration-resistant prostate cancer: member has a homologous recombination repair (HRR) gene mutation (ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, or RAD51C); AND has not had treatment in the setting of castration-resistant prostate cancer; AND requested medication will be used in combination with enzalutamide (Xtandi); AND member has had a bilateral orchiectomy OR will use the medication in combination with an LHRH agonist (e.g., goserelin, leuprolide) or antagonist (e.g., degarelix, relugolix).
Reauthorization criteria
- Continuation of therapy may be granted when there is no evidence of unacceptable toxicity or disease progression while on the current regimen for an indication covered under the initial criteria.
Approval duration
12 months